[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fzbbzeu5S3fu8XQ13w6zsFjc8LCt4PowIX4kdpx3SfGo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":62,"rows":69},"University Hospital, Geneva",[4],375,false,50,23,990189,6,286,[14,16,19,21,23,25,27,29],{"name":15,"count":11},"Pain",{"name":17,"count":18},"Coronary Artery Disease",5,{"name":20,"count":18},"Surgery",{"name":22,"count":18},"Healthy",{"name":24,"count":18},"Critical Illness",{"name":26,"count":18},"Emergencies",{"name":28,"count":18},"Stroke",{"name":30,"count":18},"Venous Thromboembolism",[32,37,42,47,52,57],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT04109755","Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer","2022-06","Pembrolizumab",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT07164287","Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment","2025-04-30","Lysergic Acid Diethylamide (LSD) or psilocybin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06108648","Efficacy of Lavender Essential Oil Chest Wraps in Infants With Bronchiolitis","2026-03-31","Lavender essential oil 10%, diluted in 90% olive oil",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04981327","The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis","2026-08-31","Apixaban 2.5 MG Oral Tablet [ELIQUIS]",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05071846","MVX-ONCO-2 in Advanced Solid Tumors","2026-11","MVX-ONCO-2",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07173127","The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters","2026-12-30","Ryeqo treatment",[63,64,65,66,67,68],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[70,95,118,141,163,185,209,251,289,320,338,363,389,407,435,453,471,497,515,533,558,585,614,632,650,679,704,731,749,767,802,830,848,866,884,910,928,952,978,1002,1028,1056,1074,1100,1127,1154,1172,1197,1222,1248,1275,1293,1311,1334,1352,1376,1394,1419,1437,1455,1477,1500,1525,1550,1568,1586,1610,1638,1656,1674,1704,1722,1750,1772,1797,1815,1841,1859,1883,1910,1928,1946,1969,1999,2025,2043,2067,2085,2117,2153,2179,2197,2223,2246,2271,2296,2322,2340,2366,2391,2417,2443,2461,2484,2508,2531,2558,2576,2594,2612,2638,2656,2682,2700,2723,2741,2764,2792,2810,2835,2858,2883,2906,2932,2950,2975,3001,3026,3051],{"intervention":46,"totalTrials":71,"cells":72},1,{"EARLY_PHASE1":73,"PHASE1":76,"PHASE2":78,"PHASE3":80,"PHASE4":82,"NA":93},{"trials":74,"activeCount":75},[],0,{"trials":77,"activeCount":75},[],{"trials":79,"activeCount":75},[],{"trials":81,"activeCount":75},[],{"trials":83,"activeCount":71,"soonestReadout":45},[84],{"nctId":43,"briefTitle":44,"status":85,"phases":86,"primaryCompletion":45,"completion":87,"start":88,"enrollment":89,"conditions":90,"interventions":92},"RECRUITING",[67],"2026-04-30","2023-12-07",400,[91],"Bronchiolitis",[46],{"trials":94,"activeCount":75},[],{"intervention":51,"totalTrials":71,"cells":96},{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":114,"NA":116},{"trials":98,"activeCount":75},[],{"trials":100,"activeCount":75},[],{"trials":102,"activeCount":75},[],{"trials":104,"activeCount":71,"soonestReadout":50},[105],{"nctId":48,"briefTitle":49,"status":106,"phases":107,"primaryCompletion":50,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NOT_YET_RECRUITING",[66],"2027-08-31","2022-09-01",1300,[112],"Deep Vein Thrombosis",[51],{"trials":115,"activeCount":75},[],{"trials":117,"activeCount":75},[],{"intervention":36,"totalTrials":71,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":135,"PHASE4":137,"NA":139},{"trials":121,"activeCount":75},[],{"trials":123,"activeCount":75},[],{"trials":125,"activeCount":71,"soonestReadout":35},[126],{"nctId":33,"briefTitle":34,"status":85,"phases":127,"primaryCompletion":35,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":134},[65],"2028-03","2020-06-02",25,[132,133],"Rectum Cancer","Rectal Cancer",[36],{"trials":136,"activeCount":75},[],{"trials":138,"activeCount":75},[],{"trials":140,"activeCount":75},[],{"intervention":56,"totalTrials":71,"cells":142},{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":161},{"trials":144,"activeCount":75},[],{"trials":146,"activeCount":71,"soonestReadout":55},[147],{"nctId":53,"briefTitle":54,"status":148,"phases":149,"primaryCompletion":55,"completion":150,"start":151,"enrollment":11,"conditions":152,"interventions":154},"ACTIVE_NOT_RECRUITING",[64],"2029-10","2024-10-22",[153],"Solid Tumor, Adult",[56],{"trials":156,"activeCount":75},[],{"trials":158,"activeCount":75},[],{"trials":160,"activeCount":75},[],{"trials":162,"activeCount":75},[],{"intervention":61,"totalTrials":71,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":166,"activeCount":75},[],{"trials":168,"activeCount":75},[],{"trials":170,"activeCount":75},[],{"trials":172,"activeCount":75},[],{"trials":174,"activeCount":75},[],{"trials":176,"activeCount":71,"soonestReadout":60},[177],{"nctId":58,"briefTitle":59,"status":85,"phases":178,"primaryCompletion":60,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":184},[68],"2027-03-30","2025-09-30",30,[183],"Uterine Fibroid",[61],{"intervention":41,"totalTrials":71,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":197},{"trials":188,"activeCount":75},[],{"trials":190,"activeCount":75},[],{"trials":192,"activeCount":75},[],{"trials":194,"activeCount":75},[],{"trials":196,"activeCount":75},[],{"trials":198,"activeCount":71,"soonestReadout":40},[199],{"nctId":38,"briefTitle":39,"status":148,"phases":200,"primaryCompletion":40,"completion":180,"start":201,"enrollment":202,"conditions":203,"interventions":208},[],"2020-06-01",376,[204,205,206,207],"Major Depressive Disorder (MDD)","Anxiety Disorders","Substance Use Disorder (SUD)","PTSD - Post Traumatic Stress Disorder",[41],{"intervention":210,"totalTrials":211,"cells":212},"Propofol",2,{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":249},{"trials":214,"activeCount":75},[],{"trials":216,"activeCount":75},[],{"trials":218,"activeCount":75},[],{"trials":220,"activeCount":75},[],{"trials":222,"activeCount":75},[223,236],{"nctId":224,"briefTitle":225,"status":226,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},"NCT00839371","Bronchoscopy and Bispectral Index (BIS) - Guided Sedation","COMPLETED",[67],"2007-11","2007-12","2005-01",84,[233],"Bronchoscopy",[210,235],"Midazolam",{"nctId":237,"briefTitle":238,"status":226,"phases":239,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":245},"NCT01115179","Propofol and Perioperative Inflammation",[67],"2005-12","2005-03",79,[244],"Inflammation",[246,247,248],"propofol","Intralipid 10%","Saline",{"trials":250,"activeCount":75},[],{"intervention":252,"totalTrials":211,"cells":253},"Pioglitazone",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":271,"PHASE4":273,"NA":287},{"trials":255,"activeCount":75},[],{"trials":257,"activeCount":75},[],{"trials":259,"activeCount":75},[260],{"nctId":261,"briefTitle":262,"status":226,"phases":263,"primaryCompletion":229,"completion":264,"start":265,"enrollment":18,"conditions":266,"interventions":268},"NCT00433069","Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone",[65],"2008-01","2007-01",[267],"Chronic Hepatitis C",[252,269,270],"Interferon Alfa-2a","Ribavirin",{"trials":272,"activeCount":75},[],{"trials":274,"activeCount":75},[275],{"nctId":276,"briefTitle":277,"status":226,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":285},"NCT01090752","Renal and Hormonal Effects of Pioglitazone",[67],"2007-10","2005-10",16,[283,284],"Diabetes","Hypertension",[252,286],"Metformin",{"trials":288,"activeCount":75},[],{"intervention":248,"totalTrials":211,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":318},{"trials":292,"activeCount":75},[],{"trials":294,"activeCount":75},[],{"trials":296,"activeCount":75},[],{"trials":298,"activeCount":75},[],{"trials":300,"activeCount":75},[301,305],{"nctId":237,"briefTitle":238,"status":226,"phases":302,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":303,"interventions":304},[67],[244],[246,247,248],{"nctId":306,"briefTitle":307,"status":308,"phases":309,"primaryCompletion":229,"completion":229,"start":310,"enrollment":311,"conditions":312,"interventions":315},"NCT00403806","Dexamethasone for Paediatric Adeno-tonsillectomy - A Dose-finding Study","TERMINATED",[67],"2005-02",215,[313,314],"Postoperative Nausea and Vomiting","Postoperative Pain",[316,317,316,248],"dexamethasone","Dexamethasone",{"trials":319,"activeCount":75},[],{"intervention":235,"totalTrials":71,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":336},{"trials":323,"activeCount":75},[],{"trials":325,"activeCount":75},[],{"trials":327,"activeCount":75},[],{"trials":329,"activeCount":75},[],{"trials":331,"activeCount":75},[332],{"nctId":224,"briefTitle":225,"status":226,"phases":333,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":334,"interventions":335},[67],[233],[210,235],{"trials":337,"activeCount":75},[],{"intervention":339,"totalTrials":71,"cells":340},"Decolonization",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":361},{"trials":342,"activeCount":75},[],{"trials":344,"activeCount":75},[],{"trials":346,"activeCount":75},[],{"trials":348,"activeCount":75},[],{"trials":350,"activeCount":75},[351],{"nctId":352,"briefTitle":353,"status":226,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT00826670","Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study",[67],"2012-08","2009-06",58,[359],"Enterobacteriaceae Infections",[339],{"trials":362,"activeCount":75},[],{"intervention":364,"totalTrials":71,"cells":365},"Physiologic saline",{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":387},{"trials":367,"activeCount":75},[],{"trials":369,"activeCount":75},[],{"trials":371,"activeCount":75},[],{"trials":373,"activeCount":75},[],{"trials":375,"activeCount":75},[376],{"nctId":377,"briefTitle":378,"status":226,"phases":379,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":385},"NCT00405977","The Effect of Magnesium Sulphate on the Time Course of Rocuronium Induced Neuromuscular Block",[67],"2008-08","2006-05",80,[384],"Neuromuscular Blockade",[364,386],"Magnesium sulphate",{"trials":388,"activeCount":75},[],{"intervention":386,"totalTrials":71,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":405},{"trials":392,"activeCount":75},[],{"trials":394,"activeCount":75},[],{"trials":396,"activeCount":75},[],{"trials":398,"activeCount":75},[],{"trials":400,"activeCount":75},[401],{"nctId":377,"briefTitle":378,"status":226,"phases":402,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":403,"interventions":404},[67],[384],[364,386],{"trials":406,"activeCount":75},[],{"intervention":408,"totalTrials":71,"cells":409},"trimethoprim-sulfamethoxazole",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":433},{"trials":411,"activeCount":75},[],{"trials":413,"activeCount":75},[],{"trials":415,"activeCount":75},[],{"trials":417,"activeCount":75},[],{"trials":419,"activeCount":75},[420],{"nctId":421,"briefTitle":422,"status":226,"phases":423,"primaryCompletion":424,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":430},"NCT00711854","Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection",[67],"2013-12","2014-02","2009-01",150,[429],"MRSA Infection",[408,431,432],"Linezolid","Rifampicin",{"trials":434,"activeCount":75},[],{"intervention":431,"totalTrials":71,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":445,"NA":451},{"trials":438,"activeCount":75},[],{"trials":440,"activeCount":75},[],{"trials":442,"activeCount":75},[],{"trials":444,"activeCount":75},[],{"trials":446,"activeCount":75},[447],{"nctId":421,"briefTitle":422,"status":226,"phases":448,"primaryCompletion":424,"completion":425,"start":426,"enrollment":427,"conditions":449,"interventions":450},[67],[429],[408,431,432],{"trials":452,"activeCount":75},[],{"intervention":432,"totalTrials":71,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":469},{"trials":456,"activeCount":75},[],{"trials":458,"activeCount":75},[],{"trials":460,"activeCount":75},[],{"trials":462,"activeCount":75},[],{"trials":464,"activeCount":75},[465],{"nctId":421,"briefTitle":422,"status":226,"phases":466,"primaryCompletion":424,"completion":425,"start":426,"enrollment":427,"conditions":467,"interventions":468},[67],[429],[408,431,432],{"trials":470,"activeCount":75},[],{"intervention":472,"totalTrials":71,"cells":473},"Garamycin Sponge",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":495},{"trials":475,"activeCount":75},[],{"trials":477,"activeCount":75},[],{"trials":479,"activeCount":75},[],{"trials":481,"activeCount":75},[],{"trials":483,"activeCount":75},[484],{"nctId":485,"briefTitle":486,"status":226,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":493},"NCT01951768","Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection",[67],"2016-06","2013-09",88,[492],"Diabetic Foot Ulcer",[472,494],"Systemic Antibiotic",{"trials":496,"activeCount":75},[],{"intervention":494,"totalTrials":71,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":507,"NA":513},{"trials":500,"activeCount":75},[],{"trials":502,"activeCount":75},[],{"trials":504,"activeCount":75},[],{"trials":506,"activeCount":75},[],{"trials":508,"activeCount":75},[509],{"nctId":485,"briefTitle":486,"status":226,"phases":510,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":511,"interventions":512},[67],[492],[472,494],{"trials":514,"activeCount":75},[],{"intervention":247,"totalTrials":71,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":531},{"trials":518,"activeCount":75},[],{"trials":520,"activeCount":75},[],{"trials":522,"activeCount":75},[],{"trials":524,"activeCount":75},[],{"trials":526,"activeCount":75},[527],{"nctId":237,"briefTitle":238,"status":226,"phases":528,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":529,"interventions":530},[67],[244],[246,247,248],{"trials":532,"activeCount":75},[],{"intervention":534,"totalTrials":71,"cells":535},"Lidocaine",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":556},{"trials":537,"activeCount":75},[],{"trials":539,"activeCount":75},[],{"trials":541,"activeCount":75},[],{"trials":543,"activeCount":75},[],{"trials":545,"activeCount":75},[546],{"nctId":547,"briefTitle":548,"status":226,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":555},"NCT00828373","The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium",[67],"2010-08","2009-08",52,[554],"Neuromuscular Block",[534],{"trials":557,"activeCount":75},[],{"intervention":559,"totalTrials":71,"cells":560},"Ivabradine",{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":567,"PHASE4":569,"NA":583},{"trials":562,"activeCount":75},[],{"trials":564,"activeCount":75},[],{"trials":566,"activeCount":75},[],{"trials":568,"activeCount":75},[],{"trials":570,"activeCount":75},[571],{"nctId":572,"briefTitle":573,"status":226,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":582},"NCT04436016","PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery",[67],"2021-12-12","2022-01-11","2020-10-05",78,[580,581],"Myocardial Injury","Myocardial Ischemia",[559],{"trials":584,"activeCount":75},[],{"intervention":586,"totalTrials":71,"cells":587},"nitrofurantoin",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":612},{"trials":589,"activeCount":75},[],{"trials":591,"activeCount":75},[],{"trials":593,"activeCount":75},[],{"trials":595,"activeCount":75},[],{"trials":597,"activeCount":75},[598],{"nctId":599,"briefTitle":600,"status":601,"phases":602,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":610},"NCT01966653","Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women","UNKNOWN",[67],"2017-05","2017-08","2013-10",600,[608,609],"Urinary Tract Infections","Cystitis",[586,611],"fosfomycin",{"trials":613,"activeCount":75},[],{"intervention":611,"totalTrials":71,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":624,"NA":630},{"trials":617,"activeCount":75},[],{"trials":619,"activeCount":75},[],{"trials":621,"activeCount":75},[],{"trials":623,"activeCount":75},[],{"trials":625,"activeCount":75},[626],{"nctId":599,"briefTitle":600,"status":601,"phases":627,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":628,"interventions":629},[67],[608,609],[586,611],{"trials":631,"activeCount":75},[],{"intervention":316,"totalTrials":71,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":642,"NA":648},{"trials":635,"activeCount":75},[],{"trials":637,"activeCount":75},[],{"trials":639,"activeCount":75},[],{"trials":641,"activeCount":75},[],{"trials":643,"activeCount":75},[644],{"nctId":306,"briefTitle":307,"status":308,"phases":645,"primaryCompletion":229,"completion":229,"start":310,"enrollment":311,"conditions":646,"interventions":647},[67],[313,314],[316,317,316,248],{"trials":649,"activeCount":75},[],{"intervention":651,"totalTrials":71,"cells":652},"Adjuvanted influenza A(H1N1) vaccines",{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":661,"NA":677},{"trials":654,"activeCount":75},[],{"trials":656,"activeCount":75},[],{"trials":658,"activeCount":75},[],{"trials":660,"activeCount":75},[],{"trials":662,"activeCount":75},[663],{"nctId":664,"briefTitle":665,"status":226,"phases":666,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":676},"NCT01022905","Vaccine Responses to Influenza A H1N1\u002F09 Immunization in High-risk Patients",[67],"2010-02","2009-11",1141,[671,672,673,674,675],"HIV Infection","Rheumatic Disease","Cancer","Transplant","Pediatrics",[651],{"trials":678,"activeCount":75},[],{"intervention":680,"totalTrials":71,"cells":681},"Prednisone",{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":702},{"trials":683,"activeCount":75},[],{"trials":685,"activeCount":75},[],{"trials":687,"activeCount":75},[],{"trials":689,"activeCount":75},[],{"trials":691,"activeCount":75},[692],{"nctId":693,"briefTitle":694,"status":226,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT05024448","Glucocorticosteroid Treatment in Acute Unilateral Vestibulopathy (Vestibular Neuronitis)",[67],"2021-06-09","2013-08-27",96,[700],"Acute Peripheral Vestibulopathy",[680],{"trials":703,"activeCount":75},[],{"intervention":705,"totalTrials":71,"cells":706},"Reducing dose of Lopinavir",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":715,"NA":729},{"trials":708,"activeCount":75},[],{"trials":710,"activeCount":75},[],{"trials":712,"activeCount":75},[],{"trials":714,"activeCount":75},[],{"trials":716,"activeCount":75},[717],{"nctId":718,"briefTitle":719,"status":601,"phases":720,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":727},"NCT00836212","Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring",[67],"2009-04","2008-03",12,[725,726],"Human Immunodeficiency Virus","HIV Infections",[705,728],"Reducing dose of efavirenz",{"trials":730,"activeCount":75},[],{"intervention":728,"totalTrials":71,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":747},{"trials":734,"activeCount":75},[],{"trials":736,"activeCount":75},[],{"trials":738,"activeCount":75},[],{"trials":740,"activeCount":75},[],{"trials":742,"activeCount":75},[743],{"nctId":718,"briefTitle":719,"status":601,"phases":744,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":745,"interventions":746},[67],[725,726],[705,728],{"trials":748,"activeCount":75},[],{"intervention":286,"totalTrials":71,"cells":750},{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":765},{"trials":752,"activeCount":75},[],{"trials":754,"activeCount":75},[],{"trials":756,"activeCount":75},[],{"trials":758,"activeCount":75},[],{"trials":760,"activeCount":75},[761],{"nctId":276,"briefTitle":277,"status":226,"phases":762,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":763,"interventions":764},[67],[283,284],[252,286],{"trials":766,"activeCount":75},[],{"intervention":768,"totalTrials":211,"cells":769},"Enoxaparin",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":776,"PHASE4":798,"NA":800},{"trials":771,"activeCount":75},[],{"trials":773,"activeCount":75},[],{"trials":775,"activeCount":75},[],{"trials":777,"activeCount":75},[778,789],{"nctId":779,"briefTitle":780,"status":308,"phases":781,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":788},"NCT04345848","Preventing COVID-19 Complications With Low- and High-dose Anticoagulation",[66],"2021-06-02","2020-04-28",160,[786,787],"COVID","Sars-CoV2",[768],{"nctId":790,"briefTitle":791,"status":226,"phases":792,"primaryCompletion":793,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":797},"NCT05878899","Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial",[66],"2023-03-13","2022-05-03",77,[30],[768],{"trials":799,"activeCount":75},[],{"trials":801,"activeCount":75},[],{"intervention":803,"totalTrials":71,"cells":804},"Cefazolin in combination with either tobramycin or gentamicin",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":826,"NA":828},{"trials":806,"activeCount":75},[],{"trials":808,"activeCount":75},[],{"trials":810,"activeCount":75},[],{"trials":812,"activeCount":75},[813],{"nctId":814,"briefTitle":815,"status":226,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":822},"NCT02717871","Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis",[66],"2020-10","2016-03",35,[821],"Keratitis; Infectious Disease (Manifestation)",[803,823,824,825],"Cycloplegic agents","Fluoroquinolones","Corticosteroids",{"trials":827,"activeCount":75},[],{"trials":829,"activeCount":75},[],{"intervention":823,"totalTrials":71,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":844,"NA":846},{"trials":833,"activeCount":75},[],{"trials":835,"activeCount":75},[],{"trials":837,"activeCount":75},[],{"trials":839,"activeCount":75},[840],{"nctId":814,"briefTitle":815,"status":226,"phases":841,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":842,"interventions":843},[66],[821],[803,823,824,825],{"trials":845,"activeCount":75},[],{"trials":847,"activeCount":75},[],{"intervention":824,"totalTrials":71,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":862,"NA":864},{"trials":851,"activeCount":75},[],{"trials":853,"activeCount":75},[],{"trials":855,"activeCount":75},[],{"trials":857,"activeCount":75},[858],{"nctId":814,"briefTitle":815,"status":226,"phases":859,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":860,"interventions":861},[66],[821],[803,823,824,825],{"trials":863,"activeCount":75},[],{"trials":865,"activeCount":75},[],{"intervention":825,"totalTrials":71,"cells":867},{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":880,"NA":882},{"trials":869,"activeCount":75},[],{"trials":871,"activeCount":75},[],{"trials":873,"activeCount":75},[],{"trials":875,"activeCount":75},[876],{"nctId":814,"briefTitle":815,"status":226,"phases":877,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":878,"interventions":879},[66],[821],[803,823,824,825],{"trials":881,"activeCount":75},[],{"trials":883,"activeCount":75},[],{"intervention":885,"totalTrials":71,"cells":886},"IV iron",{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":906,"NA":908},{"trials":888,"activeCount":75},[],{"trials":890,"activeCount":75},[],{"trials":892,"activeCount":75},[],{"trials":894,"activeCount":75},[895],{"nctId":896,"briefTitle":897,"status":226,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":8,"conditions":901,"interventions":904},"NCT02631980","HepciFer Study: Hepcidin Overexpression After Hepatectomy : Does Iron Supplementation Make Sense ?",[66],"2016-10","2015-10",[902,903],"Anemia","Postoperative Blood Loss",[885,905],"IV placebo",{"trials":907,"activeCount":75},[],{"trials":909,"activeCount":75},[],{"intervention":905,"totalTrials":71,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":924,"NA":926},{"trials":913,"activeCount":75},[],{"trials":915,"activeCount":75},[],{"trials":917,"activeCount":75},[],{"trials":919,"activeCount":75},[920],{"nctId":896,"briefTitle":897,"status":226,"phases":921,"primaryCompletion":899,"completion":899,"start":900,"enrollment":8,"conditions":922,"interventions":923},[66],[902,903],[885,905],{"trials":925,"activeCount":75},[],{"trials":927,"activeCount":75},[],{"intervention":929,"totalTrials":71,"cells":930},"Pegylated interferon alpha2a",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":948,"NA":950},{"trials":932,"activeCount":75},[],{"trials":934,"activeCount":75},[],{"trials":936,"activeCount":75},[],{"trials":938,"activeCount":75},[939],{"nctId":940,"briefTitle":941,"status":226,"phases":942,"completion":943,"start":944,"enrollment":130,"conditions":945,"interventions":947},"NCT00466219","Ribavirin\u002FPegasys Treatment of Recurrent Hepatitis C After Liver Transplant",[66],"2006-12","2002-05",[946],"Hepatitis C",[270,929],{"trials":949,"activeCount":75},[],{"trials":951,"activeCount":75},[],{"intervention":953,"totalTrials":71,"cells":954},"Zidovudine",{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":961,"PHASE4":974,"NA":976},{"trials":956,"activeCount":75},[],{"trials":958,"activeCount":75},[],{"trials":960,"activeCount":75},[],{"trials":962,"activeCount":75},[963],{"nctId":964,"briefTitle":965,"status":601,"phases":966,"primaryCompletion":967,"start":968,"enrollment":969,"conditions":970,"interventions":973},"NCT01540240","Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients",[65,66],"2012-12","2011-08",136,[971,972],"HIV","Zidovudine Adverse Reaction",[953,953],{"trials":975,"activeCount":75},[],{"trials":977,"activeCount":75},[],{"intervention":979,"totalTrials":71,"cells":980},"midazolam with 2 different levels of sedation scores",{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":987,"PHASE4":998,"NA":1000},{"trials":982,"activeCount":75},[],{"trials":984,"activeCount":75},[],{"trials":986,"activeCount":75},[],{"trials":988,"activeCount":75},[989],{"nctId":990,"briefTitle":991,"status":601,"phases":992,"completion":265,"start":993,"enrollment":994,"conditions":995,"interventions":997},"NCT00221520","Sedation in the Intensive Care Unit",[66],"2003-02",126,[24,996],"Respiratory Failure",[979],{"trials":999,"activeCount":75},[],{"trials":1001,"activeCount":75},[],{"intervention":1003,"totalTrials":71,"cells":1004},"Benazepril hydrochloride",{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1011,"PHASE4":1024,"NA":1026},{"trials":1006,"activeCount":75},[],{"trials":1008,"activeCount":75},[],{"trials":1010,"activeCount":75},[],{"trials":1012,"activeCount":75},[1013],{"nctId":1014,"briefTitle":1015,"status":226,"phases":1016,"primaryCompletion":1017,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT01095939","Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia",[66],"2015-12","2018-03","2010-04",120,[1022],"Renal Alteration",[1003],{"trials":1025,"activeCount":75},[],{"trials":1027,"activeCount":75},[],{"intervention":1029,"totalTrials":71,"cells":1030},"Pertagen®",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1037,"PHASE4":1052,"NA":1054},{"trials":1032,"activeCount":75},[],{"trials":1034,"activeCount":75},[],{"trials":1036,"activeCount":75},[],{"trials":1038,"activeCount":75},[1039],{"nctId":1040,"briefTitle":1041,"status":601,"phases":1042,"primaryCompletion":1043,"completion":1044,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1050},"NCT05193734","Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines",[65,66],"2022-08-01","2023-03-30","2022-02-07",100,[1048,1049],"Pertussis","Vaccine-Preventable Diseases",[1029,1051],"Revaxis®",{"trials":1053,"activeCount":75},[],{"trials":1055,"activeCount":75},[],{"intervention":1051,"totalTrials":71,"cells":1057},{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1064,"PHASE4":1070,"NA":1072},{"trials":1059,"activeCount":75},[],{"trials":1061,"activeCount":75},[],{"trials":1063,"activeCount":75},[],{"trials":1065,"activeCount":75},[1066],{"nctId":1040,"briefTitle":1041,"status":601,"phases":1067,"primaryCompletion":1043,"completion":1044,"start":1045,"enrollment":1046,"conditions":1068,"interventions":1069},[65,66],[1048,1049],[1029,1051],{"trials":1071,"activeCount":75},[],{"trials":1073,"activeCount":75},[],{"intervention":1075,"totalTrials":71,"cells":1076},"SARS-CoV-2 convalescent plasma",{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1083,"PHASE4":1096,"NA":1098},{"trials":1078,"activeCount":75},[],{"trials":1080,"activeCount":75},[],{"trials":1082,"activeCount":75},[],{"trials":1084,"activeCount":75},[1085],{"nctId":1086,"briefTitle":1087,"status":601,"phases":1088,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":1046,"conditions":1091,"interventions":1095},"NCT04836260","Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19",[66],"2021-12-31","2021-04-08",[1092,1093,1094],"Covid19","Immuno-Deficiency","Old Age; Debility",[1075],{"trials":1097,"activeCount":75},[],{"trials":1099,"activeCount":75},[],{"intervention":1101,"totalTrials":71,"cells":1102},"Vaccination with VZV vaccine",{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1107,"PHASE3":1109,"PHASE4":1123,"NA":1125},{"trials":1104,"activeCount":75},[],{"trials":1106,"activeCount":75},[],{"trials":1108,"activeCount":75},[],{"trials":1110,"activeCount":75},[1111],{"nctId":1112,"briefTitle":1113,"status":601,"phases":1114,"primaryCompletion":1115,"completion":1116,"start":1117,"enrollment":382,"conditions":1118,"interventions":1122},"NCT00492739","Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients",[65,66],"2022-04","2025-12","2007-06",[1119,1120,1121],"Liver Disease","Immunosuppression","Varicella",[1101],{"trials":1124,"activeCount":75},[],{"trials":1126,"activeCount":75},[],{"intervention":1128,"totalTrials":71,"cells":1129},"Lactate, Sodium",{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1150,"NA":1152},{"trials":1131,"activeCount":75},[],{"trials":1133,"activeCount":75},[],{"trials":1135,"activeCount":75},[],{"trials":1137,"activeCount":75},[1138],{"nctId":1139,"briefTitle":1140,"status":601,"phases":1141,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":552,"conditions":1145,"interventions":1148},"NCT06110429","Sodium Lactate Versus Hypertonic Saline Solution in the Treatment of Intracranial Hypertensive Episodes in Severe Brain Injured Patients",[66],"2025-06","2026-01","2024-01",[1146,1147],"Intra Cerebral Hypertension","Lactate Sodium Solution",[1128,1149],"Hypertonic saline",{"trials":1151,"activeCount":75},[],{"trials":1153,"activeCount":75},[],{"intervention":1149,"totalTrials":71,"cells":1155},{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1168,"NA":1170},{"trials":1157,"activeCount":75},[],{"trials":1159,"activeCount":75},[],{"trials":1161,"activeCount":75},[],{"trials":1163,"activeCount":75},[1164],{"nctId":1139,"briefTitle":1140,"status":601,"phases":1165,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":552,"conditions":1166,"interventions":1167},[66],[1146,1147],[1128,1149],{"trials":1169,"activeCount":75},[],{"trials":1171,"activeCount":75},[],{"intervention":1173,"totalTrials":71,"cells":1174},"nadroparine calcium",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1181,"PHASE4":1193,"NA":1195},{"trials":1176,"activeCount":75},[],{"trials":1178,"activeCount":75},[],{"trials":1180,"activeCount":75},[],{"trials":1182,"activeCount":75},[1183],{"nctId":1184,"briefTitle":1185,"status":226,"phases":1186,"primaryCompletion":1187,"completion":1188,"start":264,"enrollment":1189,"conditions":1190,"interventions":1192},"NCT00421538","Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT)",[66],"2015-05","2015-08",260,[1191],"Distal (Calf) Deep-vein Thrombosis",[1173],{"trials":1194,"activeCount":75},[],{"trials":1196,"activeCount":75},[],{"intervention":1198,"totalTrials":71,"cells":1199},"Peanut Immunotherapy",{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1201,"activeCount":75},[],{"trials":1203,"activeCount":75},[],{"trials":1205,"activeCount":75},[1206],{"nctId":1207,"briefTitle":1208,"status":308,"phases":1209,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":723,"conditions":1212,"interventions":1215},"NCT04974970","Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy",[64,65],"2022-04-19","2019-04-01",[1213,1214],"Food Allergy","Peanut Allergy",[1198],{"trials":1217,"activeCount":75},[],{"trials":1219,"activeCount":75},[],{"trials":1221,"activeCount":75},[],{"intervention":1223,"totalTrials":71,"cells":1224},"VSV-ZEBOV",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1226,"activeCount":75},[],{"trials":1228,"activeCount":75},[],{"trials":1230,"activeCount":75},[1231],{"nctId":1232,"briefTitle":1233,"status":226,"phases":1234,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":1239,"interventions":1241},"NCT02287480","VSV-ZEBOV Geneva Vaccine Trial",[64,65],"2015-04","2016-01","2014-11",115,[1240],"Ebolavirus Disease",[1223],{"trials":1243,"activeCount":75},[],{"trials":1245,"activeCount":75},[],{"trials":1247,"activeCount":75},[],{"intervention":1249,"totalTrials":71,"cells":1250},"Magnesium perfusion",{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1252,"activeCount":75},[],{"trials":1254,"activeCount":75},[],{"trials":1256,"activeCount":75},[1257],{"nctId":1258,"briefTitle":1259,"status":226,"phases":1260,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":1263,"conditions":1264,"interventions":1266},"NCT01571908","Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study",[65],"2015-07","2012-09",280,[1265],"Intubation Conditions",[1249,1267,1268],"Rocuronium","Succinylcholine",{"trials":1270,"activeCount":75},[],{"trials":1272,"activeCount":75},[],{"trials":1274,"activeCount":75},[],{"intervention":1267,"totalTrials":71,"cells":1276},{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1278,"activeCount":75},[],{"trials":1280,"activeCount":75},[],{"trials":1282,"activeCount":75},[1283],{"nctId":1258,"briefTitle":1259,"status":226,"phases":1284,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":1263,"conditions":1285,"interventions":1286},[65],[1265],[1249,1267,1268],{"trials":1288,"activeCount":75},[],{"trials":1290,"activeCount":75},[],{"trials":1292,"activeCount":75},[],{"intervention":1268,"totalTrials":71,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":75},[],{"trials":1298,"activeCount":75},[],{"trials":1300,"activeCount":75},[1301],{"nctId":1258,"briefTitle":1259,"status":226,"phases":1302,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":1263,"conditions":1303,"interventions":1304},[65],[1265],[1249,1267,1268],{"trials":1306,"activeCount":75},[],{"trials":1308,"activeCount":75},[],{"trials":1310,"activeCount":75},[],{"intervention":1312,"totalTrials":71,"cells":1313},"Vancomycin",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1328,"PHASE4":1330,"NA":1332},{"trials":1315,"activeCount":75},[],{"trials":1317,"activeCount":75},[],{"trials":1319,"activeCount":75},[1320],{"nctId":1321,"briefTitle":1322,"status":601,"phases":1323,"start":1324,"enrollment":698,"conditions":1325,"interventions":1327},"NCT00150852","Prevention of Gastrostomy-Related Wound Infection by Vancomycin in Carriers of Methicillin-Resistant Staphylococcus Aureus.",[65],"2004-09",[1326],"Wound Infection",[1312],{"trials":1329,"activeCount":75},[],{"trials":1331,"activeCount":75},[],{"trials":1333,"activeCount":75},[],{"intervention":269,"totalTrials":71,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1337,"activeCount":75},[],{"trials":1339,"activeCount":75},[],{"trials":1341,"activeCount":75},[1342],{"nctId":261,"briefTitle":262,"status":226,"phases":1343,"primaryCompletion":229,"completion":264,"start":265,"enrollment":18,"conditions":1344,"interventions":1345},[65],[267],[252,269,270],{"trials":1347,"activeCount":75},[],{"trials":1349,"activeCount":75},[],{"trials":1351,"activeCount":75},[],{"intervention":1353,"totalTrials":71,"cells":1354},"ticagrelor 180 mg administrated alone",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1356,"activeCount":75},[],{"trials":1358,"activeCount":75},[],{"trials":1360,"activeCount":75},[1361],{"nctId":1362,"briefTitle":1363,"status":226,"phases":1364,"primaryCompletion":1235,"completion":1235,"start":1365,"enrollment":1366,"conditions":1367,"interventions":1368},"NCT02435563","Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling",[65],"2014-08",22,[22],[1353,1369],"Ticagrelor adjusted dose + ritonavir 100mg",{"trials":1371,"activeCount":75},[],{"trials":1373,"activeCount":75},[],{"trials":1375,"activeCount":75},[],{"intervention":1369,"totalTrials":71,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1379,"activeCount":75},[],{"trials":1381,"activeCount":75},[],{"trials":1383,"activeCount":75},[1384],{"nctId":1362,"briefTitle":1363,"status":226,"phases":1385,"primaryCompletion":1235,"completion":1235,"start":1365,"enrollment":1366,"conditions":1386,"interventions":1387},[65],[22],[1353,1369],{"trials":1389,"activeCount":75},[],{"trials":1391,"activeCount":75},[],{"trials":1393,"activeCount":75},[],{"intervention":1395,"totalTrials":71,"cells":1396},"flurbiprofen",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1398,"activeCount":75},[],{"trials":1400,"activeCount":75},[],{"trials":1402,"activeCount":75},[1403],{"nctId":1404,"briefTitle":1405,"status":226,"phases":1406,"primaryCompletion":550,"completion":550,"start":668,"enrollment":1407,"conditions":1408,"interventions":1410},"NCT01026714","CYP2C9 Activity Evaluated With a Simple Finger Prick",[64,65],10,[1409],"Healthy Volunteers",[1395,1411,1412],"flurbiprofen, rifampicin","flurbiprofen + fluconazole",{"trials":1414,"activeCount":75},[],{"trials":1416,"activeCount":75},[],{"trials":1418,"activeCount":75},[],{"intervention":1411,"totalTrials":71,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1422,"activeCount":75},[],{"trials":1424,"activeCount":75},[],{"trials":1426,"activeCount":75},[1427],{"nctId":1404,"briefTitle":1405,"status":226,"phases":1428,"primaryCompletion":550,"completion":550,"start":668,"enrollment":1407,"conditions":1429,"interventions":1430},[64,65],[1409],[1395,1411,1412],{"trials":1432,"activeCount":75},[],{"trials":1434,"activeCount":75},[],{"trials":1436,"activeCount":75},[],{"intervention":1412,"totalTrials":71,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1440,"activeCount":75},[],{"trials":1442,"activeCount":75},[],{"trials":1444,"activeCount":75},[1445],{"nctId":1404,"briefTitle":1405,"status":226,"phases":1446,"primaryCompletion":550,"completion":550,"start":668,"enrollment":1407,"conditions":1447,"interventions":1448},[64,65],[1409],[1395,1411,1412],{"trials":1450,"activeCount":75},[],{"trials":1452,"activeCount":75},[],{"trials":1454,"activeCount":75},[],{"intervention":1456,"totalTrials":71,"cells":1457},"Nicotine",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1471,"PHASE4":1473,"NA":1475},{"trials":1459,"activeCount":75},[],{"trials":1461,"activeCount":75},[],{"trials":1463,"activeCount":75},[1464],{"nctId":1465,"briefTitle":1466,"status":308,"phases":1467,"primaryCompletion":551,"completion":551,"start":279,"enrollment":1468,"conditions":1469,"interventions":1470},"NCT00553709","Study of Nicotine for the Prevention of PONV",[65],200,[313],[1456],{"trials":1472,"activeCount":75},[],{"trials":1474,"activeCount":75},[],{"trials":1476,"activeCount":75},[],{"intervention":1478,"totalTrials":71,"cells":1479},"epoetinum",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1481,"activeCount":75},[],{"trials":1483,"activeCount":75},[],{"trials":1485,"activeCount":75},[1486],{"nctId":1487,"briefTitle":1488,"status":226,"phases":1489,"primaryCompletion":356,"completion":356,"start":1490,"enrollment":382,"conditions":1491,"interventions":1493},"NCT00676234","Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure",[65],"2008-05",[1492],"Acute Renal Failure",[1478],{"trials":1495,"activeCount":75},[],{"trials":1497,"activeCount":75},[],{"trials":1499,"activeCount":75},[],{"intervention":1501,"totalTrials":71,"cells":1502},"Erythromycin",{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1504,"activeCount":75},[],{"trials":1506,"activeCount":75},[],{"trials":1508,"activeCount":75},[1509],{"nctId":1510,"briefTitle":1511,"status":226,"phases":1512,"primaryCompletion":1513,"completion":1513,"start":426,"enrollment":1514,"conditions":1515,"interventions":1518},"NCT00827216","The Effect of Intravenous Erythromycin on Gastric Emptying in Non-fasted Patients Before Emergency Total Anesthesia",[65],"2013-04",132,[1516,1517],"Aspiration of Gastric Contents","Gastric Emptying",[1501],{"trials":1520,"activeCount":75},[],{"trials":1522,"activeCount":75},[],{"trials":1524,"activeCount":75},[],{"intervention":1526,"totalTrials":71,"cells":1527},"Clonazepam",{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1529,"activeCount":75},[],{"trials":1531,"activeCount":75},[],{"trials":1533,"activeCount":75},[1534],{"nctId":1535,"briefTitle":1536,"status":226,"phases":1537,"primaryCompletion":1538,"completion":1538,"start":1019,"enrollment":130,"conditions":1539,"interventions":1541},"NCT01291316","GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation",[64,65],"2011-11",[1540],"Neuropathic Pain",[1526,1542,1543],"Tolterodine","clobazam",{"trials":1545,"activeCount":75},[],{"trials":1547,"activeCount":75},[],{"trials":1549,"activeCount":75},[],{"intervention":1542,"totalTrials":71,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1553,"activeCount":75},[],{"trials":1555,"activeCount":75},[],{"trials":1557,"activeCount":75},[1558],{"nctId":1535,"briefTitle":1536,"status":226,"phases":1559,"primaryCompletion":1538,"completion":1538,"start":1019,"enrollment":130,"conditions":1560,"interventions":1561},[64,65],[1540],[1526,1542,1543],{"trials":1563,"activeCount":75},[],{"trials":1565,"activeCount":75},[],{"trials":1567,"activeCount":75},[],{"intervention":1543,"totalTrials":71,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1571,"activeCount":75},[],{"trials":1573,"activeCount":75},[],{"trials":1575,"activeCount":75},[1576],{"nctId":1535,"briefTitle":1536,"status":226,"phases":1577,"primaryCompletion":1538,"completion":1538,"start":1019,"enrollment":130,"conditions":1578,"interventions":1579},[64,65],[1540],[1526,1542,1543],{"trials":1581,"activeCount":75},[],{"trials":1583,"activeCount":75},[],{"trials":1585,"activeCount":75},[],{"intervention":1587,"totalTrials":71,"cells":1588},"Magnesium Sulfate",{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1590,"activeCount":75},[],{"trials":1592,"activeCount":75},[],{"trials":1594,"activeCount":75},[1595],{"nctId":1596,"briefTitle":1597,"status":226,"phases":1598,"primaryCompletion":1599,"completion":1599,"start":1600,"enrollment":1601,"conditions":1602,"interventions":1603},"NCT01440933","Efficacy of Sugammadex in Magnesium Pretreated Patients",[65],"2012-06","2011-09",32,[554],[1587],{"trials":1605,"activeCount":75},[],{"trials":1607,"activeCount":75},[],{"trials":1609,"activeCount":75},[],{"intervention":1611,"totalTrials":71,"cells":1612},"Dexamethasone 3 mg",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1614,"activeCount":75},[],{"trials":1616,"activeCount":75},[],{"trials":1618,"activeCount":75},[1619],{"nctId":1620,"briefTitle":1621,"status":308,"phases":1622,"primaryCompletion":1623,"completion":1624,"start":1625,"enrollment":1626,"conditions":1627,"interventions":1629},"NCT01975727","Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting",[65],"2017-11-08","2017-11-09","2012-09-03",256,[313,1628],"Vomiting",[1611,1630,1631],"Dexamethasone 6 mg","Dexamethasone 12 mg",{"trials":1633,"activeCount":75},[],{"trials":1635,"activeCount":75},[],{"trials":1637,"activeCount":75},[],{"intervention":1630,"totalTrials":71,"cells":1639},{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1641,"activeCount":75},[],{"trials":1643,"activeCount":75},[],{"trials":1645,"activeCount":75},[1646],{"nctId":1620,"briefTitle":1621,"status":308,"phases":1647,"primaryCompletion":1623,"completion":1624,"start":1625,"enrollment":1626,"conditions":1648,"interventions":1649},[65],[313,1628],[1611,1630,1631],{"trials":1651,"activeCount":75},[],{"trials":1653,"activeCount":75},[],{"trials":1655,"activeCount":75},[],{"intervention":1631,"totalTrials":71,"cells":1657},{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1659,"activeCount":75},[],{"trials":1661,"activeCount":75},[],{"trials":1663,"activeCount":75},[1664],{"nctId":1620,"briefTitle":1621,"status":308,"phases":1665,"primaryCompletion":1623,"completion":1624,"start":1625,"enrollment":1626,"conditions":1666,"interventions":1667},[65],[313,1628],[1611,1630,1631],{"trials":1669,"activeCount":75},[],{"trials":1671,"activeCount":75},[],{"trials":1673,"activeCount":75},[],{"intervention":1675,"totalTrials":71,"cells":1676},"IMA950\u002FPoly-ICLC",{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1678,"activeCount":75},[],{"trials":1680,"activeCount":75},[],{"trials":1682,"activeCount":75},[1683],{"nctId":1684,"briefTitle":1685,"status":226,"phases":1686,"primaryCompletion":1687,"completion":1688,"start":1689,"enrollment":1690,"conditions":1691,"interventions":1696},"NCT03665545","Pembrolizumab in Association With the IMA950\u002FPoly-ICLC for Relapsing Glioblastoma",[64,65],"2023-12-31","2024-04-24","2018-10-25",18,[1692,1693,1694,1695],"Glioblastoma Multiforme","Glioblastoma, Adult","Glioma of Brain","Glioblastoma Multiforme of Brain",[1675,1697],"IMA950\u002FPoly-ICLC and pembrolizumab",{"trials":1699,"activeCount":75},[],{"trials":1701,"activeCount":75},[],{"trials":1703,"activeCount":75},[],{"intervention":1697,"totalTrials":71,"cells":1705},{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1707,"activeCount":75},[],{"trials":1709,"activeCount":75},[],{"trials":1711,"activeCount":75},[1712],{"nctId":1684,"briefTitle":1685,"status":226,"phases":1713,"primaryCompletion":1687,"completion":1688,"start":1689,"enrollment":1690,"conditions":1714,"interventions":1715},[64,65],[1692,1693,1694,1695],[1675,1697],{"trials":1717,"activeCount":75},[],{"trials":1719,"activeCount":75},[],{"trials":1721,"activeCount":75},[],{"intervention":1723,"totalTrials":71,"cells":1724},"Propranolol hydrochloride",{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1726,"activeCount":75},[],{"trials":1728,"activeCount":75},[],{"trials":1730,"activeCount":75},[1731],{"nctId":1732,"briefTitle":1733,"status":1734,"phases":1735,"primaryCompletion":1736,"completion":1737,"start":488,"enrollment":1738,"conditions":1739,"interventions":1743},"NCT01988831","Efficacy of Propranolol Treatment to Prevent Melanoma Progression","SUSPENDED",[65],"2022-01","2022-03",450,[1740,1741,1742],"Stages III Skin Melanoma","Stages II Skin Melanoma","Stage IB Skin Melanoma",[1723],{"trials":1745,"activeCount":75},[],{"trials":1747,"activeCount":75},[],{"trials":1749,"activeCount":75},[],{"intervention":1751,"totalTrials":71,"cells":1752},"Ketamine",{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1766,"PHASE4":1768,"NA":1770},{"trials":1754,"activeCount":75},[],{"trials":1756,"activeCount":75},[],{"trials":1758,"activeCount":75},[1759],{"nctId":1760,"briefTitle":1761,"status":226,"phases":1762,"primaryCompletion":1763,"completion":1763,"start":279,"enrollment":784,"conditions":1764,"interventions":1765},"NCT00618423","The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery",[65],"2013-03",[314],[1751],{"trials":1767,"activeCount":75},[],{"trials":1769,"activeCount":75},[],{"trials":1771,"activeCount":75},[],{"intervention":1773,"totalTrials":71,"cells":1774},"IMA 950",{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1776,"activeCount":75},[],{"trials":1778,"activeCount":75},[],{"trials":1780,"activeCount":75},[1781],{"nctId":1782,"briefTitle":1783,"status":226,"phases":1784,"primaryCompletion":818,"completion":818,"start":1785,"enrollment":1786,"conditions":1787,"interventions":1789},"NCT01920191","Phase I\u002FII Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma",[64,65],"2013-08",19,[1788],"CNS Tumor, Adult",[1773,1790],"Poly ICLC",{"trials":1792,"activeCount":75},[],{"trials":1794,"activeCount":75},[],{"trials":1796,"activeCount":75},[],{"intervention":1790,"totalTrials":71,"cells":1798},{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1800,"activeCount":75},[],{"trials":1802,"activeCount":75},[],{"trials":1804,"activeCount":75},[1805],{"nctId":1782,"briefTitle":1783,"status":226,"phases":1806,"primaryCompletion":818,"completion":818,"start":1785,"enrollment":1786,"conditions":1807,"interventions":1808},[64,65],[1788],[1773,1790],{"trials":1810,"activeCount":75},[],{"trials":1812,"activeCount":75},[],{"trials":1814,"activeCount":75},[],{"intervention":1816,"totalTrials":71,"cells":1817},"Adalimumab",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1822,"PHASE3":1835,"PHASE4":1837,"NA":1839},{"trials":1819,"activeCount":75},[],{"trials":1821,"activeCount":75},[],{"trials":1823,"activeCount":75},[1824],{"nctId":1825,"briefTitle":1826,"status":226,"phases":1827,"primaryCompletion":264,"completion":1828,"start":1829,"enrollment":1830,"conditions":1831,"interventions":1833},"NCT00470509","Adalimumab in Severe and Acute Sciatica",[65],"2008-06","2005-05",61,[1832],"Sciatica",[1816,1834],"Placebos",{"trials":1836,"activeCount":75},[],{"trials":1838,"activeCount":75},[],{"trials":1840,"activeCount":75},[],{"intervention":1834,"totalTrials":71,"cells":1842},{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1847,"PHASE3":1853,"PHASE4":1855,"NA":1857},{"trials":1844,"activeCount":75},[],{"trials":1846,"activeCount":75},[],{"trials":1848,"activeCount":75},[1849],{"nctId":1825,"briefTitle":1826,"status":226,"phases":1850,"primaryCompletion":264,"completion":1828,"start":1829,"enrollment":1830,"conditions":1851,"interventions":1852},[65],[1832],[1816,1834],{"trials":1854,"activeCount":75},[],{"trials":1856,"activeCount":75},[],{"trials":1858,"activeCount":75},[],{"intervention":1860,"totalTrials":71,"cells":1861},"ferucarbotran",{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1875,"PHASE3":1877,"PHASE4":1879,"NA":1881},{"trials":1863,"activeCount":75},[],{"trials":1865,"activeCount":75},[1866],{"nctId":1867,"briefTitle":1868,"status":308,"phases":1869,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":18,"conditions":1872,"interventions":1874},"NCT00453817","Islet of Langerhans Graft Monitoring by Magnetic Resonance Imaging",[64],"2010-06","2005-06",[1873],"Type 1 Diabetes Mellitus",[1860],{"trials":1876,"activeCount":75},[],{"trials":1878,"activeCount":75},[],{"trials":1880,"activeCount":75},[],{"trials":1882,"activeCount":75},[],{"intervention":1884,"totalTrials":71,"cells":1885},"Voriconazole 200mg",{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1902,"PHASE3":1904,"PHASE4":1906,"NA":1908},{"trials":1887,"activeCount":75},[],{"trials":1889,"activeCount":75},[1890],{"nctId":1891,"briefTitle":1892,"status":601,"phases":1893,"primaryCompletion":1894,"completion":1895,"start":1896,"enrollment":1897,"conditions":1898,"interventions":1899},"NCT05264142","Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status",[64],"2023-03-31","2023-08-31","2022-04-01",45,[22],[1884,1900,1901],"FluvoxaMINE 50 Mg Oral","Omeprazole 10 MG Oral",{"trials":1903,"activeCount":75},[],{"trials":1905,"activeCount":75},[],{"trials":1907,"activeCount":75},[],{"trials":1909,"activeCount":75},[],{"intervention":1900,"totalTrials":71,"cells":1911},{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1913,"activeCount":75},[],{"trials":1915,"activeCount":75},[1916],{"nctId":1891,"briefTitle":1892,"status":601,"phases":1917,"primaryCompletion":1894,"completion":1895,"start":1896,"enrollment":1897,"conditions":1918,"interventions":1919},[64],[22],[1884,1900,1901],{"trials":1921,"activeCount":75},[],{"trials":1923,"activeCount":75},[],{"trials":1925,"activeCount":75},[],{"trials":1927,"activeCount":75},[],{"intervention":1901,"totalTrials":71,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1931,"activeCount":75},[],{"trials":1933,"activeCount":75},[1934],{"nctId":1891,"briefTitle":1892,"status":601,"phases":1935,"primaryCompletion":1894,"completion":1895,"start":1896,"enrollment":1897,"conditions":1936,"interventions":1937},[64],[22],[1884,1900,1901],{"trials":1939,"activeCount":75},[],{"trials":1941,"activeCount":75},[],{"trials":1943,"activeCount":75},[],{"trials":1945,"activeCount":75},[],{"intervention":1947,"totalTrials":71,"cells":1948},"Patient controlled intravenous analgesia",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1961,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1950,"activeCount":75},[],{"trials":1952,"activeCount":75},[1953],{"nctId":1954,"briefTitle":1955,"status":226,"phases":1956,"primaryCompletion":550,"completion":1538,"start":1957,"enrollment":819,"conditions":1958,"interventions":1960},"NCT01607996","Effect of Epidural Anesthesia on Pancreatic Perfusion and Clinical Outcome in Patients With Severe Acute Pancreatitis",[64],"2005-07",[1959],"Severe Acute Pancreatitis",[1947],{"trials":1962,"activeCount":75},[],{"trials":1964,"activeCount":75},[],{"trials":1966,"activeCount":75},[],{"trials":1968,"activeCount":75},[],{"intervention":1970,"totalTrials":71,"cells":1971},"Sorafenib dose escalation",{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1991,"PHASE3":1993,"PHASE4":1995,"NA":1997},{"trials":1973,"activeCount":75},[],{"trials":1975,"activeCount":75},[1976],{"nctId":1977,"briefTitle":1978,"status":226,"phases":1979,"primaryCompletion":1980,"completion":1981,"start":1982,"enrollment":1983,"conditions":1984,"interventions":1990},"NCT00884416","Sorafenib in Newly Diagnosed High Grade Glioma",[64],"2011-12","2012-03","2009-03",17,[1985,1986,1987,1988,1989],"Glioblastoma","Gliosarcoma","Anaplastic Astrocytoma","Anaplastic Oligoastrocytoma","Anaplastic Oligodendroglioma",[1970],{"trials":1992,"activeCount":75},[],{"trials":1994,"activeCount":75},[],{"trials":1996,"activeCount":75},[],{"trials":1998,"activeCount":75},[],{"intervention":2000,"totalTrials":71,"cells":2001},"Nab paclitaxel",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2017,"PHASE3":2019,"PHASE4":2021,"NA":2023},{"trials":2003,"activeCount":75},[],{"trials":2005,"activeCount":75},[2006],{"nctId":2007,"briefTitle":2008,"status":601,"phases":2009,"primaryCompletion":2010,"completion":2011,"start":2012,"enrollment":1690,"conditions":2013,"interventions":2015},"NCT04000906","PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis",[64],"2023-12-12","2024-12","2020-11-11",[2014],"Peritoneal Carcinomatosis",[2000,2016],"Cisplatin",{"trials":2018,"activeCount":75},[],{"trials":2020,"activeCount":75},[],{"trials":2022,"activeCount":75},[],{"trials":2024,"activeCount":75},[],{"intervention":2016,"totalTrials":71,"cells":2026},{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2035,"PHASE3":2037,"PHASE4":2039,"NA":2041},{"trials":2028,"activeCount":75},[],{"trials":2030,"activeCount":75},[2031],{"nctId":2007,"briefTitle":2008,"status":601,"phases":2032,"primaryCompletion":2010,"completion":2011,"start":2012,"enrollment":1690,"conditions":2033,"interventions":2034},[64],[2014],[2000,2016],{"trials":2036,"activeCount":75},[],{"trials":2038,"activeCount":75},[],{"trials":2040,"activeCount":75},[],{"trials":2042,"activeCount":75},[],{"intervention":2044,"totalTrials":71,"cells":2045},"Prasugrel",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2059,"PHASE3":2061,"PHASE4":2063,"NA":2065},{"trials":2047,"activeCount":75},[],{"trials":2049,"activeCount":75},[2050],{"nctId":2051,"briefTitle":2052,"status":226,"phases":2053,"primaryCompletion":2054,"completion":1600,"start":2055,"enrollment":1407,"conditions":2056,"interventions":2057},"NCT01346800","Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy Volunteers",[64],"2011-06","2011-02",[1409],[2044,2058],"Ritonavir",{"trials":2060,"activeCount":75},[],{"trials":2062,"activeCount":75},[],{"trials":2064,"activeCount":75},[],{"trials":2066,"activeCount":75},[],{"intervention":2058,"totalTrials":71,"cells":2068},{"EARLY_PHASE1":2069,"PHASE1":2071,"PHASE2":2077,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2070,"activeCount":75},[],{"trials":2072,"activeCount":75},[2073],{"nctId":2051,"briefTitle":2052,"status":226,"phases":2074,"primaryCompletion":2054,"completion":1600,"start":2055,"enrollment":1407,"conditions":2075,"interventions":2076},[64],[1409],[2044,2058],{"trials":2078,"activeCount":75},[],{"trials":2080,"activeCount":75},[],{"trials":2082,"activeCount":75},[],{"trials":2084,"activeCount":75},[],{"intervention":270,"totalTrials":2086,"cells":2087},3,{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2098,"PHASE4":2104,"NA":2106},{"trials":2089,"activeCount":75},[],{"trials":2091,"activeCount":75},[],{"trials":2093,"activeCount":75},[2094],{"nctId":261,"briefTitle":262,"status":226,"phases":2095,"primaryCompletion":229,"completion":264,"start":265,"enrollment":18,"conditions":2096,"interventions":2097},[65],[267],[252,269,270],{"trials":2099,"activeCount":75},[2100],{"nctId":940,"briefTitle":941,"status":226,"phases":2101,"completion":943,"start":944,"enrollment":130,"conditions":2102,"interventions":2103},[66],[946],[270,929],{"trials":2105,"activeCount":75},[],{"trials":2107,"activeCount":75},[2108],{"nctId":2109,"briefTitle":2110,"status":226,"phases":2111,"primaryCompletion":2112,"completion":2112,"start":818,"enrollment":1983,"conditions":2113,"interventions":2115},"NCT02760355","Extrahepatic Insulin Resistance in Chronic Hepatitis C",[68],"2018-06-01",[2114],"Insulin Resistance",[2116,270],"Ledipasvir 90 mg\u002FSofosbuvir 400 mg",{"intervention":2118,"totalTrials":211,"cells":2119},"Nitrous Oxide",{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2140},{"trials":2121,"activeCount":75},[],{"trials":2123,"activeCount":75},[],{"trials":2125,"activeCount":75},[],{"trials":2127,"activeCount":75},[],{"trials":2129,"activeCount":75},[2130],{"nctId":2131,"briefTitle":2132,"status":308,"phases":2133,"primaryCompletion":2134,"completion":2134,"start":489,"enrollment":2135,"conditions":2136,"interventions":2139},"NCT02489097","International Substudy Enigma2 on Postoperative Cognitive Disorders",[67],"2016-05",140,[2137,2138],"Anesthesia","Delirium, Dementia, Amnestic, Cognitive Disorders",[2118],{"trials":2141,"activeCount":75},[2142],{"nctId":2143,"briefTitle":2144,"status":226,"phases":2145,"primaryCompletion":2146,"completion":2147,"start":2148,"enrollment":1897,"conditions":2149,"interventions":2152},"NCT04185233","Distraction and Nitrous Oxide for Venous Puncture",[68],"2020-05-21","2020-09-30","2018-04-30",[2150,15,2151],"Anxiety","Venous Puncture",[2118],{"intervention":2154,"totalTrials":71,"cells":2155},"Allocation to the Lab-score group",{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2160,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2157,"activeCount":75},[],{"trials":2159,"activeCount":75},[],{"trials":2161,"activeCount":75},[],{"trials":2163,"activeCount":75},[],{"trials":2165,"activeCount":75},[],{"trials":2167,"activeCount":75},[2168],{"nctId":2169,"briefTitle":2170,"status":226,"phases":2171,"primaryCompletion":2172,"completion":2172,"start":2173,"enrollment":2174,"conditions":2175,"interventions":2177},"NCT02179398","Impact of the Lab-score on Antibiotic Prescription Rate in Children With Fever Without Source",[68],"2013-07","2010-09",278,[2176],"Fever Without Source",[2154,2178],"Allocation to the control group",{"intervention":2178,"totalTrials":71,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2185,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2182,"activeCount":75},[],{"trials":2184,"activeCount":75},[],{"trials":2186,"activeCount":75},[],{"trials":2188,"activeCount":75},[],{"trials":2190,"activeCount":75},[],{"trials":2192,"activeCount":75},[2193],{"nctId":2169,"briefTitle":2170,"status":226,"phases":2194,"primaryCompletion":2172,"completion":2172,"start":2173,"enrollment":2174,"conditions":2195,"interventions":2196},[68],[2176],[2154,2178],{"intervention":2198,"totalTrials":71,"cells":2199},"Antibiotic duration",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2208,"NA":2210},{"trials":2201,"activeCount":75},[],{"trials":2203,"activeCount":75},[],{"trials":2205,"activeCount":75},[],{"trials":2207,"activeCount":75},[],{"trials":2209,"activeCount":75},[],{"trials":2211,"activeCount":75},[2212],{"nctId":2213,"briefTitle":2214,"status":226,"phases":2215,"primaryCompletion":2216,"completion":2217,"start":2218,"enrollment":2219,"conditions":2220,"interventions":2222},"NCT03615807","Less Infections for the Diabetic Foot",[68],"2020-02-29","2020-03-31","2017-02-16",182,[2221],"Diabetic Foot",[2198],{"intervention":2224,"totalTrials":71,"cells":2225},"methylene blue",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2227,"activeCount":75},[],{"trials":2229,"activeCount":75},[],{"trials":2231,"activeCount":75},[],{"trials":2233,"activeCount":75},[],{"trials":2235,"activeCount":75},[],{"trials":2237,"activeCount":75},[2238],{"nctId":2239,"briefTitle":2240,"status":226,"phases":2241,"completion":2242,"start":230,"enrollment":1366,"conditions":2243,"interventions":2245},"NCT00513032","Interaction Between Anaesthetics and Methylene Blue",[],"2007-04",[2244],"Hyperparathyroidism",[2224],{"intervention":2247,"totalTrials":71,"cells":2248},"Parathyroid supplementation",{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2255,"PHASE4":2257,"NA":2259},{"trials":2250,"activeCount":75},[],{"trials":2252,"activeCount":75},[],{"trials":2254,"activeCount":75},[],{"trials":2256,"activeCount":75},[],{"trials":2258,"activeCount":75},[],{"trials":2260,"activeCount":75},[2261],{"nctId":2262,"briefTitle":2263,"status":226,"phases":2264,"primaryCompletion":2265,"completion":2265,"start":2266,"enrollment":2267,"conditions":2268,"interventions":2270},"NCT02249780","Assessing Parathyroid Glands Vascularisation by ICG Fluoroscopy",[68],"2016-02","2014-09",146,[2269],"Parathyroid Function Low Adverse Event",[2247],{"intervention":2272,"totalTrials":71,"cells":2273},"CYP3A4\u002F5 and P-gp genotyping",{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2278,"PHASE3":2280,"PHASE4":2282,"NA":2284},{"trials":2275,"activeCount":75},[],{"trials":2277,"activeCount":75},[],{"trials":2279,"activeCount":75},[],{"trials":2281,"activeCount":75},[],{"trials":2283,"activeCount":75},[],{"trials":2285,"activeCount":75},[2286],{"nctId":2287,"briefTitle":2288,"status":226,"phases":2289,"primaryCompletion":2290,"completion":2290,"start":2291,"enrollment":2292,"conditions":2293,"interventions":2295},"NCT03112525","DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic",[],"2021-01-07","2017-06-28",300,[2294],"Anticoagulants and Bleeding Disorders",[2272],{"intervention":2297,"totalTrials":71,"cells":2298},"Genotyping by single nulcetoide polymorphism.",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2307,"NA":2309},{"trials":2300,"activeCount":75},[],{"trials":2302,"activeCount":75},[],{"trials":2304,"activeCount":75},[],{"trials":2306,"activeCount":75},[],{"trials":2308,"activeCount":75},[],{"trials":2310,"activeCount":75},[2311],{"nctId":2312,"briefTitle":2313,"status":601,"phases":2314,"primaryCompletion":2315,"completion":2316,"start":2317,"enrollment":2318,"conditions":2319,"interventions":2321},"NCT04249674","Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol",[],"2022-11-01","2022-12","2019-11-04",172,[2320,15],"Interaction",[2297],{"intervention":2116,"totalTrials":71,"cells":2323},{"EARLY_PHASE1":2324,"PHASE1":2326,"PHASE2":2328,"PHASE3":2330,"PHASE4":2332,"NA":2334},{"trials":2325,"activeCount":75},[],{"trials":2327,"activeCount":75},[],{"trials":2329,"activeCount":75},[],{"trials":2331,"activeCount":75},[],{"trials":2333,"activeCount":75},[],{"trials":2335,"activeCount":75},[2336],{"nctId":2109,"briefTitle":2110,"status":226,"phases":2337,"primaryCompletion":2112,"completion":2112,"start":818,"enrollment":1983,"conditions":2338,"interventions":2339},[68],[2114],[2116,270],{"intervention":2341,"totalTrials":71,"cells":2342},"Ropivacaine 0.5% Injectable Solution",{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2349,"PHASE4":2351,"NA":2353},{"trials":2344,"activeCount":75},[],{"trials":2346,"activeCount":75},[],{"trials":2348,"activeCount":75},[],{"trials":2350,"activeCount":75},[],{"trials":2352,"activeCount":75},[],{"trials":2354,"activeCount":75},[2355],{"nctId":2356,"briefTitle":2357,"status":601,"phases":2358,"primaryCompletion":2359,"completion":2360,"start":2361,"enrollment":2362,"conditions":2363,"interventions":2365},"NCT04048889","Addition of Popliteal Plexus Block to Continuous Femoral Nerve Block for Total Knee Arthroplasty",[68],"2022-03-01","2022-07-01","2019-07-22",66,[2364],"Pain, Postoperative",[2341,2341,2341],{"intervention":2367,"totalTrials":71,"cells":2368},"Antibiotic durations",{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2370,"activeCount":75},[],{"trials":2372,"activeCount":75},[],{"trials":2374,"activeCount":75},[],{"trials":2376,"activeCount":75},[],{"trials":2378,"activeCount":75},[],{"trials":2380,"activeCount":75},[2381],{"nctId":2382,"briefTitle":2383,"status":226,"phases":2384,"primaryCompletion":2385,"completion":2386,"start":2387,"enrollment":1020,"conditions":2388,"interventions":2390},"NCT03602209","Short vs. Long Antibiotic Treatment of Implant-free Osteoarticular Infections",[68],"2018-02-28","2018-05-18","2015-03-01",[2389],"Implant Infection",[2367],{"intervention":2392,"totalTrials":71,"cells":2393},"Calcium Dobesilate",{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2400,"PHASE4":2402,"NA":2404},{"trials":2395,"activeCount":75},[],{"trials":2397,"activeCount":75},[],{"trials":2399,"activeCount":75},[],{"trials":2401,"activeCount":75},[],{"trials":2403,"activeCount":75},[],{"trials":2405,"activeCount":75},[2406],{"nctId":2407,"briefTitle":2408,"status":601,"phases":2409,"primaryCompletion":2410,"completion":2411,"start":2412,"enrollment":2413,"conditions":2414,"interventions":2416},"NCT04922996","Bioavailability and Pharmacokinetics of Calcium Dobesilate (Doxium®) in the Nasal Mucosal Tissue, Saliva and Blood of Treated Patients",[],"2021-05-26","2021-08","2021-04-15",14,[2415],"Biological Availability",[2392],{"intervention":2418,"totalTrials":71,"cells":2419},"chlorthalidone",{"EARLY_PHASE1":2420,"PHASE1":2422,"PHASE2":2424,"PHASE3":2426,"PHASE4":2428,"NA":2430},{"trials":2421,"activeCount":75},[],{"trials":2423,"activeCount":75},[],{"trials":2425,"activeCount":75},[],{"trials":2427,"activeCount":75},[],{"trials":2429,"activeCount":75},[],{"trials":2431,"activeCount":75},[2432],{"nctId":2433,"briefTitle":2434,"status":226,"phases":2435,"primaryCompletion":603,"completion":603,"start":2436,"enrollment":2437,"conditions":2438,"interventions":2441},"NCT01083017","Resistant Arterial Hypertension Cohort Study",[],"2011-04",74,[284,2439,2440],"Essential Hypertension","Resistant Hypertension",[2418,2442],"standardized anti-hypertensive treatment",{"intervention":2442,"totalTrials":71,"cells":2444},{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2446,"activeCount":75},[],{"trials":2448,"activeCount":75},[],{"trials":2450,"activeCount":75},[],{"trials":2452,"activeCount":75},[],{"trials":2454,"activeCount":75},[],{"trials":2456,"activeCount":75},[2457],{"nctId":2433,"briefTitle":2434,"status":226,"phases":2458,"primaryCompletion":603,"completion":603,"start":2436,"enrollment":2437,"conditions":2459,"interventions":2460},[],[284,2439,2440],[2418,2442],{"intervention":2462,"totalTrials":71,"cells":2463},"Omeprazole",{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2468,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2465,"activeCount":75},[],{"trials":2467,"activeCount":75},[],{"trials":2469,"activeCount":75},[],{"trials":2471,"activeCount":75},[],{"trials":2473,"activeCount":75},[],{"trials":2475,"activeCount":75},[2476],{"nctId":2477,"briefTitle":2478,"status":601,"phases":2479,"primaryCompletion":1017,"completion":1017,"start":2480,"enrollment":1046,"conditions":2481,"interventions":2483},"NCT02438072","Drug Metabolism and Antidepressant",[68],"2014-12",[2482],"Depression",[2462],{"intervention":2485,"totalTrials":71,"cells":2486},"Treatment interruption",{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2493,"PHASE4":2495,"NA":2497},{"trials":2488,"activeCount":75},[],{"trials":2490,"activeCount":75},[],{"trials":2492,"activeCount":75},[],{"trials":2494,"activeCount":75},[],{"trials":2496,"activeCount":75},[],{"trials":2498,"activeCount":75},[2499],{"nctId":2500,"briefTitle":2501,"status":226,"phases":2502,"completion":280,"start":2503,"enrollment":2504,"conditions":2505,"interventions":2507},"NCT00113126","Staccato: A Trial of CD4 Guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection",[68],"2002-01",526,[671,2506],"AIDS",[2485],{"intervention":2509,"totalTrials":71,"cells":2510},"mouth wash with morphine",{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2517,"PHASE4":2519,"NA":2521},{"trials":2512,"activeCount":75},[],{"trials":2514,"activeCount":75},[],{"trials":2516,"activeCount":75},[],{"trials":2518,"activeCount":75},[],{"trials":2520,"activeCount":75},[],{"trials":2522,"activeCount":75},[2523],{"nctId":2524,"briefTitle":2525,"status":226,"phases":2526,"primaryCompletion":264,"completion":2527,"start":229,"enrollment":181,"conditions":2528,"interventions":2530},"NCT00613743","Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and\u002For Radiotherapy Induced Mucositis",[68],"2008-12",[673,2529],"Mucositis",[2509],{"intervention":2532,"totalTrials":71,"cells":2533},"Raltegravir for the first 2 weeks",{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2538,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2535,"activeCount":75},[],{"trials":2537,"activeCount":75},[],{"trials":2539,"activeCount":75},[],{"trials":2541,"activeCount":75},[],{"trials":2543,"activeCount":75},[],{"trials":2545,"activeCount":75},[2546],{"nctId":2547,"briefTitle":2548,"status":601,"phases":2549,"primaryCompletion":2550,"completion":1019,"start":668,"enrollment":2551,"conditions":2552,"interventions":2554},"NCT00944957","Patient Preference, Sleep Quality, and Anxiety\u002FDepression: A Comparison of Raltegravir and Efavirenz",[68],"2009-12",60,[2553,726],"Sleep Disorders",[2532,2555,2556,2557],"Efavirenz for the last 2 weeks","Efavirenz for the first 2 weeks","Raltegravir for the last 2 weeks",{"intervention":2555,"totalTrials":71,"cells":2559},{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2564,"PHASE3":2566,"PHASE4":2568,"NA":2570},{"trials":2561,"activeCount":75},[],{"trials":2563,"activeCount":75},[],{"trials":2565,"activeCount":75},[],{"trials":2567,"activeCount":75},[],{"trials":2569,"activeCount":75},[],{"trials":2571,"activeCount":75},[2572],{"nctId":2547,"briefTitle":2548,"status":601,"phases":2573,"primaryCompletion":2550,"completion":1019,"start":668,"enrollment":2551,"conditions":2574,"interventions":2575},[68],[2553,726],[2532,2555,2556,2557],{"intervention":2556,"totalTrials":71,"cells":2577},{"EARLY_PHASE1":2578,"PHASE1":2580,"PHASE2":2582,"PHASE3":2584,"PHASE4":2586,"NA":2588},{"trials":2579,"activeCount":75},[],{"trials":2581,"activeCount":75},[],{"trials":2583,"activeCount":75},[],{"trials":2585,"activeCount":75},[],{"trials":2587,"activeCount":75},[],{"trials":2589,"activeCount":75},[2590],{"nctId":2547,"briefTitle":2548,"status":601,"phases":2591,"primaryCompletion":2550,"completion":1019,"start":668,"enrollment":2551,"conditions":2592,"interventions":2593},[68],[2553,726],[2532,2555,2556,2557],{"intervention":2557,"totalTrials":71,"cells":2595},{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2600,"PHASE3":2602,"PHASE4":2604,"NA":2606},{"trials":2597,"activeCount":75},[],{"trials":2599,"activeCount":75},[],{"trials":2601,"activeCount":75},[],{"trials":2603,"activeCount":75},[],{"trials":2605,"activeCount":75},[],{"trials":2607,"activeCount":75},[2608],{"nctId":2547,"briefTitle":2548,"status":601,"phases":2609,"primaryCompletion":2550,"completion":1019,"start":668,"enrollment":2551,"conditions":2610,"interventions":2611},[68],[2553,726],[2532,2555,2556,2557],{"intervention":2613,"totalTrials":71,"cells":2614},"Remifentanil",{"EARLY_PHASE1":2615,"PHASE1":2617,"PHASE2":2619,"PHASE3":2621,"PHASE4":2623,"NA":2625},{"trials":2616,"activeCount":75},[],{"trials":2618,"activeCount":75},[],{"trials":2620,"activeCount":75},[],{"trials":2622,"activeCount":75},[],{"trials":2624,"activeCount":75},[],{"trials":2626,"activeCount":75},[2627],{"nctId":2628,"briefTitle":2629,"status":2630,"phases":2631,"primaryCompletion":2632,"completion":2316,"start":2633,"enrollment":75,"conditions":2634,"interventions":2636},"NCT02683837","Pupillometry Guided Remifentanil Administration In Pediatric Anesthesia","WITHDRAWN",[68],"2016-11","2016-04",[2137,15,2635],"Child",[2613,2637],"Sevoflurane",{"intervention":2637,"totalTrials":71,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2650},{"trials":2641,"activeCount":75},[],{"trials":2643,"activeCount":75},[],{"trials":2645,"activeCount":75},[],{"trials":2647,"activeCount":75},[],{"trials":2649,"activeCount":75},[],{"trials":2651,"activeCount":75},[2652],{"nctId":2628,"briefTitle":2629,"status":2630,"phases":2653,"primaryCompletion":2632,"completion":2316,"start":2633,"enrollment":75,"conditions":2654,"interventions":2655},[68],[2137,15,2635],[2613,2637],{"intervention":2657,"totalTrials":71,"cells":2658},"inhalation of salbutamol",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2660,"activeCount":75},[],{"trials":2662,"activeCount":75},[],{"trials":2664,"activeCount":75},[],{"trials":2666,"activeCount":75},[],{"trials":2668,"activeCount":75},[],{"trials":2670,"activeCount":75},[2671],{"nctId":2672,"briefTitle":2673,"status":226,"phases":2674,"completion":1117,"start":1324,"enrollment":181,"conditions":2675,"interventions":2680},"NCT00498251","Prevention of Lung Edema After Thoracic Surgery",[68],[2676,2677,2137,2678,2679],"Lung Injury, Acute","Thoracotomy","Intensive Care, Surgical","Extravascular Lung Water",[2657,2681],"ipratropium",{"intervention":2681,"totalTrials":71,"cells":2683},{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2688,"PHASE3":2690,"PHASE4":2692,"NA":2694},{"trials":2685,"activeCount":75},[],{"trials":2687,"activeCount":75},[],{"trials":2689,"activeCount":75},[],{"trials":2691,"activeCount":75},[],{"trials":2693,"activeCount":75},[],{"trials":2695,"activeCount":75},[2696],{"nctId":2672,"briefTitle":2673,"status":226,"phases":2697,"completion":1117,"start":1324,"enrollment":181,"conditions":2698,"interventions":2699},[68],[2676,2677,2137,2678,2679],[2657,2681],{"intervention":2701,"totalTrials":71,"cells":2702},"etravirine",{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2707,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2704,"activeCount":75},[],{"trials":2706,"activeCount":75},[],{"trials":2708,"activeCount":75},[],{"trials":2710,"activeCount":75},[],{"trials":2712,"activeCount":75},[],{"trials":2714,"activeCount":75},[2715],{"nctId":2716,"briefTitle":2717,"status":226,"phases":2718,"primaryCompletion":2719,"completion":356,"start":2719,"enrollment":8,"conditions":2720,"interventions":2721},"NCT00792584","Patient Preference, Sleep Quality, and Anxiety\u002FDepression: A Randomized Comparison of Etravirine and Efavirenz",[68],"2008-11",[2553],[2701,2722],"efavirenz",{"intervention":2722,"totalTrials":71,"cells":2724},{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2729,"PHASE3":2731,"PHASE4":2733,"NA":2735},{"trials":2726,"activeCount":75},[],{"trials":2728,"activeCount":75},[],{"trials":2730,"activeCount":75},[],{"trials":2732,"activeCount":75},[],{"trials":2734,"activeCount":75},[],{"trials":2736,"activeCount":75},[2737],{"nctId":2716,"briefTitle":2717,"status":226,"phases":2738,"primaryCompletion":2719,"completion":356,"start":2719,"enrollment":8,"conditions":2739,"interventions":2740},[68],[2553],[2701,2722],{"intervention":2742,"totalTrials":71,"cells":2743},"lidocaine and ropivacaine injection through catheters",{"EARLY_PHASE1":2744,"PHASE1":2746,"PHASE2":2748,"PHASE3":2750,"PHASE4":2752,"NA":2754},{"trials":2745,"activeCount":75},[],{"trials":2747,"activeCount":75},[],{"trials":2749,"activeCount":75},[],{"trials":2751,"activeCount":75},[],{"trials":2753,"activeCount":75},[],{"trials":2755,"activeCount":75},[2756],{"nctId":2757,"briefTitle":2758,"status":226,"phases":2759,"primaryCompletion":1235,"completion":1235,"start":2760,"enrollment":2761,"conditions":2762,"interventions":2763},"NCT03376178","Catheter Orifice Configuration (Six-hole Versus End-hole) on Post-operative Analgesia After Total Knee Arthroplasty.",[68],"2014-05",72,[15],[2742],{"intervention":2765,"totalTrials":71,"cells":2766},"Desogestrel 0.075 milligram",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2771,"PHASE3":2773,"PHASE4":2775,"NA":2777},{"trials":2768,"activeCount":75},[],{"trials":2770,"activeCount":75},[],{"trials":2772,"activeCount":75},[],{"trials":2774,"activeCount":75},[],{"trials":2776,"activeCount":75},[],{"trials":2778,"activeCount":75},[2779],{"nctId":2780,"briefTitle":2781,"status":308,"phases":2782,"primaryCompletion":2783,"completion":2784,"start":2785,"enrollment":2786,"conditions":2787,"interventions":2790},"NCT05174195","Does Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year?",[68],"2018-03-01","2019-09-30","2016-08-15",67,[2788,2789],"Contraception","Progestogen Adverse Reaction",[2765,2791],"Implanon NXT® subdermal implant",{"intervention":2791,"totalTrials":71,"cells":2793},{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2800,"PHASE4":2802,"NA":2804},{"trials":2795,"activeCount":75},[],{"trials":2797,"activeCount":75},[],{"trials":2799,"activeCount":75},[],{"trials":2801,"activeCount":75},[],{"trials":2803,"activeCount":75},[],{"trials":2805,"activeCount":75},[2806],{"nctId":2780,"briefTitle":2781,"status":308,"phases":2807,"primaryCompletion":2783,"completion":2784,"start":2785,"enrollment":2786,"conditions":2808,"interventions":2809},[68],[2788,2789],[2765,2791],{"intervention":2811,"totalTrials":71,"cells":2812},"GSTA1 genotyping",{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2819,"PHASE4":2821,"NA":2823},{"trials":2814,"activeCount":75},[],{"trials":2816,"activeCount":75},[],{"trials":2818,"activeCount":75},[],{"trials":2820,"activeCount":75},[],{"trials":2822,"activeCount":75},[],{"trials":2824,"activeCount":75},[2825],{"nctId":2826,"briefTitle":2827,"status":601,"phases":2828,"primaryCompletion":1142,"completion":1142,"start":2829,"enrollment":1189,"conditions":2830,"interventions":2834},"NCT04822532","Precision Dosing of Busulfan in Children Undergoing HSCT",[68],"2021-06-15",[2831,2832,2833],"Hematopoietic Stem Cell Transplantation","Allogeneic Hematopoietic Stem Cell Transplantation","Autologous Hematopoietic Stem Cell Transplantation",[2811],{"intervention":2836,"totalTrials":71,"cells":2837},"nadroparin",{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2842,"PHASE3":2844,"PHASE4":2846,"NA":2848},{"trials":2839,"activeCount":75},[],{"trials":2841,"activeCount":75},[],{"trials":2843,"activeCount":75},[],{"trials":2845,"activeCount":75},[],{"trials":2847,"activeCount":75},[],{"trials":2849,"activeCount":75},[2850],{"nctId":2851,"briefTitle":2852,"status":308,"phases":2853,"completion":2854,"start":2855,"conditions":2856,"interventions":2857},"NCT00303407","Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care",[],"2002-07","2001-01",[673,30],[2836],{"intervention":2859,"totalTrials":71,"cells":2860},"Sufentanil",{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2865,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2862,"activeCount":75},[],{"trials":2864,"activeCount":75},[],{"trials":2866,"activeCount":75},[],{"trials":2868,"activeCount":75},[],{"trials":2870,"activeCount":75},[],{"trials":2872,"activeCount":75},[2873],{"nctId":2874,"briefTitle":2875,"status":226,"phases":2876,"primaryCompletion":2877,"completion":2877,"start":2878,"enrollment":2879,"conditions":2880,"interventions":2882},"NCT02831101","Sufentanil Bispectral Index Elderly",[68],"2015-11","2012-02",71,[2881],"Loss of Consciousness",[2859],{"intervention":2884,"totalTrials":71,"cells":2885},"levodopa and benserazide",{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2890,"PHASE3":2892,"PHASE4":2894,"NA":2896},{"trials":2887,"activeCount":75},[],{"trials":2889,"activeCount":75},[],{"trials":2891,"activeCount":75},[],{"trials":2893,"activeCount":75},[],{"trials":2895,"activeCount":75},[],{"trials":2897,"activeCount":75},[2898],{"nctId":2899,"briefTitle":2900,"status":226,"phases":2901,"primaryCompletion":551,"completion":551,"start":2902,"enrollment":723,"conditions":2903,"interventions":2905},"NCT00941265","Effect of Dopaminergic Medication on Recovery of Aphasia",[68],"2007-02",[2904],"Aphasia",[2884],{"intervention":2907,"totalTrials":71,"cells":2908},"Two week's arm - drugs",{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2915,"PHASE4":2917,"NA":2919},{"trials":2910,"activeCount":75},[],{"trials":2912,"activeCount":75},[],{"trials":2914,"activeCount":75},[],{"trials":2916,"activeCount":75},[],{"trials":2918,"activeCount":75},[],{"trials":2920,"activeCount":75},[2921],{"nctId":2922,"briefTitle":2923,"status":226,"phases":2924,"primaryCompletion":2925,"completion":2386,"start":2926,"enrollment":2927,"conditions":2928,"interventions":2930},"NCT03615781","Two Versus Four Weeks of Antibiotic Treatment in Native Joint Arthritis",[68],"2018-04-01","2015-06-01",85,[2929],"Arthritis, Septic",[2907,2931],"Four week's arm - drugs",{"intervention":2931,"totalTrials":71,"cells":2933},{"EARLY_PHASE1":2934,"PHASE1":2936,"PHASE2":2938,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2935,"activeCount":75},[],{"trials":2937,"activeCount":75},[],{"trials":2939,"activeCount":75},[],{"trials":2941,"activeCount":75},[],{"trials":2943,"activeCount":75},[],{"trials":2945,"activeCount":75},[2946],{"nctId":2922,"briefTitle":2923,"status":226,"phases":2947,"primaryCompletion":2925,"completion":2386,"start":2926,"enrollment":2927,"conditions":2948,"interventions":2949},[68],[2929],[2907,2931],{"intervention":2951,"totalTrials":71,"cells":2952},"IV iron administration",{"EARLY_PHASE1":2953,"PHASE1":2955,"PHASE2":2957,"PHASE3":2959,"PHASE4":2961,"NA":2963},{"trials":2954,"activeCount":75},[],{"trials":2956,"activeCount":75},[],{"trials":2958,"activeCount":75},[],{"trials":2960,"activeCount":75},[],{"trials":2962,"activeCount":75},[],{"trials":2964,"activeCount":75},[2965],{"nctId":2966,"briefTitle":2967,"status":226,"phases":2968,"primaryCompletion":2969,"completion":2969,"start":2970,"enrollment":2971,"conditions":2972,"interventions":2974},"NCT06108258","Newborn Phosphocalcic Metabolism After Intravenous Iron Administration During Pregnancy",[],"2023-03-03","2022-09-23",43,[2973],"Iron Induced Hypophosphatemia",[2951],{"intervention":2976,"totalTrials":71,"cells":2977},"Blood test",{"EARLY_PHASE1":2978,"PHASE1":2980,"PHASE2":2982,"PHASE3":2984,"PHASE4":2986,"NA":2988},{"trials":2979,"activeCount":75},[],{"trials":2981,"activeCount":75},[],{"trials":2983,"activeCount":75},[],{"trials":2985,"activeCount":75},[],{"trials":2987,"activeCount":75},[],{"trials":2989,"activeCount":75},[2990],{"nctId":2991,"briefTitle":2992,"status":226,"phases":2993,"primaryCompletion":2994,"completion":2147,"start":2995,"enrollment":2996,"conditions":2997,"interventions":3000},"NCT04188444","Prothrombotic Biomarkers and Ovarian Stimulation",[],"2020-03-01","2017-03-01",65,[2998,2999],"Sterility, Female","Reproductive Technology, Assisted",[2976],{"intervention":3002,"totalTrials":71,"cells":3003},"standard sedation",{"EARLY_PHASE1":3004,"PHASE1":3006,"PHASE2":3008,"PHASE3":3010,"PHASE4":3012,"NA":3014},{"trials":3005,"activeCount":75},[],{"trials":3007,"activeCount":75},[],{"trials":3009,"activeCount":75},[],{"trials":3011,"activeCount":75},[],{"trials":3013,"activeCount":75},[],{"trials":3015,"activeCount":75},[3016],{"nctId":3017,"briefTitle":3018,"status":308,"phases":3019,"primaryCompletion":2480,"completion":2480,"start":3020,"enrollment":382,"conditions":3021,"interventions":3025},"NCT00913861","Non-pharmacological Intervention for Colonoscopy",[68],"2009-05",[3022,3023,3024],"Colonoscopy","Sedation","Hypnosis",[3002],{"intervention":3027,"totalTrials":71,"cells":3028},"Diet supplementation",{"EARLY_PHASE1":3029,"PHASE1":3031,"PHASE2":3033,"PHASE3":3035,"PHASE4":3037,"NA":3039},{"trials":3030,"activeCount":75},[],{"trials":3032,"activeCount":75},[],{"trials":3034,"activeCount":75},[],{"trials":3036,"activeCount":75},[],{"trials":3038,"activeCount":75},[],{"trials":3040,"activeCount":75},[3041],{"nctId":3042,"briefTitle":3043,"status":226,"phases":3044,"primaryCompletion":1980,"completion":967,"start":3045,"enrollment":3046,"conditions":3047,"interventions":3050},"NCT03029572","Micro-nutritional Status and Gut Microbiota in Morbidly Obese Patients Before and After Gastric Bypass",[68],"2009-02",90,[3048,3049],"Obesity","Bariatric Surgery Candidate",[3027],{"intervention":3052,"totalTrials":71,"cells":3053},"REACH",{"EARLY_PHASE1":3054,"PHASE1":3056,"PHASE2":3058,"PHASE3":3060,"PHASE4":3062,"NA":3064},{"trials":3055,"activeCount":75},[],{"trials":3057,"activeCount":75},[],{"trials":3059,"activeCount":75},[],{"trials":3061,"activeCount":75},[],{"trials":3063,"activeCount":75},[],{"trials":3065,"activeCount":75},[3066],{"nctId":3067,"briefTitle":3068,"status":226,"phases":3069,"primaryCompletion":3070,"completion":3071,"start":3072,"enrollment":3073,"conditions":3074,"interventions":3077},"NCT03847454","REACH Personal Mobility Device Testing",[68],"2019-08-12","2019-09-05","2019-02-27",57,[3075,3076],"Musculoskeletal Diseases or Conditions","Rehabilitation",[3052]]